NASDAQ:ALXO
Alx Oncology Holdings Inc.
Alx Oncology Holdings Inc. reported net income of −$101.7M in fiscal 2025. Free cash flow was −$84.4M, and the diluted share count rose 2.8%.Summary generated from Alx Oncology Holdings Inc.'s SEC filings. Latest annual report filed Mar 9, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROIC−130.0%
Return on equity−145.7%
Debt / equity0.39
Free cash flow−$84.4M
FCF marginn/a
Share count change+2.8%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | n/a | n/a | n/a |
| Operating income | −84 | −127 | −170 | −142 | −104 |
| Net income | −83 | −123 | −161 | −135 | −102 |
| Free cash flow | −69 | −91 | −132 | −122 | −84 |
Recent filings
- 4Insider transaction report
Aug 18, 2026 - 4Insider transaction report
Aug 18, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KDirector or officer change
Jun 30, 2026 - 8-KEntry into a material agreement
Jun 26, 2026 - 8-KResults of a shareholder vote
Jun 11, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 8, 2026